Immatics (IMTX) Change in Receivables (2019 - 2026)
Immatics (IMTX) posted Change in Receivables of -$3.4 million for Q4 2025, down 133.62% sequentially from -$1.4 million in Q3 2025, and down 8.71% YoY from -$3.7 million in Q4 2024.
Analysis
Immatics (IMTX) Change in Receivables (2019 - 2026) Analysis & Trends
Immatics has reported Change in Receivables for 7 years, with the latest figure at -$3.4 million in Q4 2025.
- Quarterly Change in Receivables fell 8.71% year-over-year to -$3.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$433406.6 (up 76.66% YoY) and the FY2025 annual result came in at -$273414.3, up 85.68% from the prior year.
- Change in Receivables slipped to -$3.4 million in Q4 2025 per IMTX's latest filing, from -$1.4 million in the prior quarter.
- Over five years, Change in Receivables peaked at $4.1 million in Q2 2025 and troughed at -$3.8 million in Q4 2023.
- A 5-year average of -$263618.7 and a median of -$131326.2 in 2024 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 1479.64% in 2023, down 13576.12% in 2023.
- Over 5 years, Change in Receivables stood at $50334.7 in 2021, then slumped by 43.25% to $28566.9 in 2022, then slumped by 13576.12% to -$3.8 million in 2023, then climbed by 19.34% to -$3.1 million in 2024, then declined by 8.71% to -$3.4 million in 2025.
- According to Business Quant data, Change in Receivables over the past three periods registered -$3.4 million, -$1.4 million, and $4.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | -1.55 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.55 Mn |
| Mar 31, 2026 | 2.28 Mn |
| Dec 31, 2025 | -3.38 Mn |
| Sep 30, 2025 | -1.44 Mn |
| Jun 30, 2025 | 4.12 Mn |
| Mar 31, 2025 | 270,334.30 |
| Dec 31, 2024 | -3.11 Mn |
| Sep 30, 2024 | -154,848.95 |
| Jun 30, 2024 | -1.11 Mn |
| Mar 31, 2024 | 2.51 Mn |
| Dec 31, 2023 | -3.85 Mn |
| Sep 30, 2023 | -201,389.24 |
| Jun 30, 2023 | -107,803.51 |
| Mar 31, 2023 | 944,540.80 |
| Dec 31, 2022 | 28,566.93 |
| Sep 30, 2022 | -178,464.56 |
| Jun 30, 2022 | -233,685.41 |
| Mar 31, 2022 | -68,462.60 |
| Dec 31, 2021 | 50,334.72 |
| Sep 30, 2021 | -8,255.01 |